Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: Multicentre, single-arm, phase 2 study

British Journal of Haematology

Volumn 165, Issue 4, 2014, Pages 510-518

  Wang, Michael ^a   Popplewell, Leslie L ^b   Collins, Robert H ^c   Winter, Jane N ^d   Goy, Andre ^e   Kaminski, Mark S ^f   Bartlett, Nancy L ^g   Johnston, Patrick B ^h   Lister, John ⁱ   Fanning, Suzanne R ^j   Tuscano, Joseph M ^k   Beck, J Thaddeus ^l   Kaya, Hakan ^m   Robeva, Anna ⁿ   Fan, Jenna ⁿ   Klimovsky, Judith ⁿ   Cheung, Wing ⁿ   Cherfi, Azzeddine ⁿ   O'Connor, Owen A ^o  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MAYO CLINIC   (United States)

ⁱ WESTERN PENNSYLVANIA HOSPITAL   (United States)

^j GREENVILLE HOSPITAL SYSTEM   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l Highlands Oncology Group   (United States)

^m Cancer Care Northwest   (United States)

ⁿ NOVARTIS PHARMA AG   (Switzerland)

^o Department of Medicine   (United States)

more..

Author keywords

Bortezomib; Everolimus; Mammalian target of rapamycin; Mantle cell lymphoma; Relapsed refractory disease

Indexed keywords

BORTEZOMIB; EVEROLIMUS;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLURRED VISION; CANCER GROWTH; CONSTIPATION; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERANCE; DYSGEUSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INSOMNIA; LEUKOCYTE COUNT; LIMB PAIN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OROPHARYNX PAIN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

BORTEZOMIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MANTLE CELL LYMPHOMA; RELAPSED/REFRACTORY DISEASE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PAIN; PNEUMONIA; PYRAZINES; SALVAGE THERAPY; SIROLIMUS; TREATMENT OUTCOME;

EID: 84899475041     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12780     Document Type: Article

References (36)

1. Ansell, S.M., Inwards, D.J., Rowland, K.M. Jr, Flynn, P.J., Morton, R.F., Moore, D.F. Jr, Kaufmann, S.H., Ghobrial, I., Kurtin, P.J., Maurer, M., Allmer, C. & Witzig, T.E. (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer, 113, 508-514.
2. Ansell, S.M., Tang, H., Kurtin, P.J., Koenig, P.A., Inwards, D.J., Shah, K., Ziesmer, S.C., Feldman, A.L., Rao, R., Gupta, M., Erlichman, C. & Witzig, T.E. (2011) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a multi-center phase 2 study. Lancet Oncology, 12, 361-368.
3. Bjornsti, M.A. & Houghton, P.J. (2004) The TOR pathway: a target for cancer therapy. Nature Reviews - Cancer, 4, 335-348.
4. Cheson, B.D. (2007) The International Harmonization Project for response criteria in lymphoma clinical trials. Hematology and Oncology Clinics of North America, 21, 841-854.
5. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
6. Civallero, M., Cosenza, M., Marcheselli, L., Pozzi, S. & Sacchi, S. (2012) NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. Expert Opinion on Investigational Drugs, 21, 1597-1606.
7. Cohen, P.L., Kurtin, P.J., Donovan, K.A. & Hanson, C.A. (1998) Bone marrow and peripheral blood involvement in mantle cell lymphoma. British Journal of Haematology, 101, 302-310.
8. Dal, C.J., Zancai, P., Terrin, L., Guidoboni, M., Ponzoni, M., Pavan, A., Spina, M., Bergamin, S., Rizzo, S., Tirelli, U., De Rossi, A., Doglioni, C. & Dolcetti, R. (2008) Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood, 111, 5142-5151.
9. Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., Sasazuki, T., Shirasawa, S., Geuna, M., Frattini, M., Baselga, J., Gallicchio, M., Biffo, S. & Bardelli, A. (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. Journal of Clinical Investigation, 120, 2858-2866.
10. Dreyling, M., Thieblemont, C., Gallamini, A., Arcaini, L., Campo, E., Hermine, O., Kluin-Nelemans, J.C., Ladetto, M., Le Gouill, S., Iannitto, E., Pileri, S., Rodriguez, J., Schmitz, N., Wotherspoon, A., Zinzani, P. & Zucca, E. (2013) ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Annals of Oncology, 24, 857-877.
11. Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. & Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 4867-4874.
12. Galimberti, S. & Petrini, M. (2010) Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma. Cancer Managagement and Research, 2, 181-189.
13. Goy, A., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Nasta, S., O'Connor, O.A., Shi, H., Boral, A.L. & Fisher, R.I. (2009) Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Annals of Oncology, 20, 520-525.
14. Goy, A., Sinha, R., Williams, M.E., Besisik, S.K., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T. & Witzig, T.E. (2013) Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. Journal of Clinical Oncology, 31, 3688-3695.
15. Haritunians, T., Mori, A., O'Kelly, J., Luong, Q.T., Giles, F.J. & Koeffler, H.P. (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia, 21, 333-339.
16. Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., Hanushevsky, O., Clancy, J., Hewes, B., Moore, L. & Coiffier, B. (2009) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 27, 3822-3829.
17. Hess, G., Keller, U., Atta, J., Buske, C., Borchmann, P., Medler, C., Witzens-Harig, M. & Dreyling, M.H. (2011) Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report of an ongoing phase I/II trial. Blood (ASH Annual Meeting Abstracts), 118, 2697.
18. Iyer, G., Hanrahan, A.J., Milowsky, M.I., Al-Ahmadie, H., Scott, S.N., Janakiraman, M., Pirun, M., Sander, C., Socci, N.D., Ostrovnaya, I., Viale, A., Heguy, A., Peng, L., Chan, T.A., Bochner, B., Bajorin, D.F., Berger, M.F., Taylor, B.S. & Solit, D.B. (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science, 338, 221.
19. Katzenberger, T., Kienle, D., Stilgenbauer, S., Holler, S., Schilling, C., Mader, U., Puppe, B., Petzoldt, C., Sander, S., Bullinger, L., Stocklein, H., Kalla, J., Hartmann, E., Adam, P., Ott, M.M., Muller-Hermelink, H.K., Rosenwald, A. & Ott, G. (2008) Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. British Journal of Haematology, 142, 538-550.
20. Kim, A., Park, S., Lee, J.E., Jang, W.S., Lee, S.J., Kang, H.J. & Lee, S.S. (2012) The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Leukemia Research, 36, 912-920.
21. Martin, P. & Leonard, J. (2011) Is there a role for "watch and wait" in patients with mantle cell lymphoma? Seminars in Hematology, 48, 189-193.
22. Meric-Bernstam, F., Akcakanat, A., Chen, H., Do, K.A., Sangai, T., Adkins, F., Gonzalez-Angulo, A.M., Rashid, A., Crosby, K., Dong, M., Phan, A.T., Wolff, R.A., Gupta, S., Mills, G.B. & Yao, J. (2012) PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clinical Cancer Research, 18, 1777-1789.
23. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. Version 1. 2013. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. Accessed June 27, 2013.
24. O'Connor, O.A., Moskowitz, C., Portlock, C., Hamlin, P., Straus, D., Dumitrescu, O., Sarasohn, D., Gonen, M., Butos, J., Neylon, E., Hamelers, R., Mac-Gregor, C.B., Blumel, S., Zelenetz, A.D., Gordon, L., Wright, J.J., Vose, J., Cooper, B. & Winter, J. (2009) Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. British Journal of Haematology, 145, 34-39.
25. Peponi, E., Drakos, E., Reyes, G., Leventaki, V., Rassidakis, G.Z. & Medeiros, L.J. (2006) Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. American Journal of Pathology, 169, 2171-2180.
26. Perez-Galan, P., Dreyling, M. & Wiestner, A. (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood, 117, 26-38.
27. Renner, C., Zinzani, P.L., Gressin, R., Klingbiel, D., Dietrich, P.Y., Hitz, F., Bargetzi, M., Mingrone, W., Martinelli, G., Trojan, A., Bouabdallah, K., Lohri, A., Gyan, E., Biaggi, C., Cogliatti, S., Bertoni, F., Ghielmini, M., Brauchli, P. & Ketterer, N. (2012) A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 97, 1085-1091.
28. Rizzatti, E.G., Falcão, R.P., Panepucci, R.A., Proto-Siqueira, R., Anselmo-Lima, W.T., Okamoto, O.K. & Zago, M.A. (2005) Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. British Journal of Haematology, 130, 516-526.
29. Romaguera, J.E., Medeiros, L.J., Hagemeister, F.B., Fayad, L.E., Rodriguez, M.A., Pro, B., Younes, A., McLaughlin, P., Goy, A., Sarris, A.H., Dang, N.H., Samaniego, F., Brown, H.M., Gagneja, H.K. & Cabanillas, F. (2003) Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer, 97, 586-591.
30. Rosenwald, A., Wright, G., Wiestner, A., Chan, W.C., Connors, J.M., Campo, E., Gascoyne, R.D., Grogan, T.M., Muller-Hermelink, H.K., Smeland, E.B., Chiorazzi, M., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Henrickson, S., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Montserrat, E., Bosch, F., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Fisher, R.I., Miller, T.P., Leblanc, M., Ott, G., Kvaloy, S., Holte, H., Delabie, J. & Staudt, L.M. (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3, 185-197.
31. Rosich, L., Xargay-Torrent, S., Lopez-Guerra, M., Campo, E., Colomer, D. & Roue, G. (2012) Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Clinical Cancer Research, 18, 5278-5289.
32. Rudelius, M., Pittaluga, S., Nishizuka, S., Pham, T.H., Fend, F., Jaffe, E.S., Quintanilla-Martinez, L. & Raffeld, M. (2006) Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood, 108, 1668-1676.
33. Schatz, J.H. (2011) Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies. Current Oncology Reports, 13, 398-406.
34. Weigelt, B., Warne, P.H. & Downward, J. (2011) PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene, 2011, 3222-3233.
35. Witzig, T.E., Geyer, S.M., Ghobrial, I., Inwards, D.J., Fonseca, R., Kurtin, P., Ansell, S.M., Luyrun, R., Flynn, P.J., Morton, R.F., Dakhil, S.R., Gross, H. & Kaufmann, S.H. (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. Journal of Clinical Oncology, 2005, 5347-5356.
36. Witzig, T.E., Reeder, C.B., Laplant, B.R., Gupta, M., Johnston, P.B., Micallef, I.N., Porrata, L.F., Ansell, S.M., Colgan, J.P., Jacobsen, E.D., Ghobrial, I.M. & Habermann, T.M. (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia, 25, 341-347.